 | | Vol. 22.04 – 1 February, 2021 |
| |
|
|
| To avoid unwanted immune recognition, scientists designed a lentiviral vector system that allowed selective CRISPR antigen removal from tumor cells.
[Immunity] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators conducted a pooled CRISPR screen in human hematopoietic stem and progenitor cells that correlated ELANE mutations with neutrophil maturation potential.
[Cell Stem Cell] |
|
|
|
| Researchers analyzed data from 44 patients with elapsed or refractory B-cell malignancies who received CD19-targeted chimeric antigen receptor-engineered on a Phase I/II trial.
[Blood] |
|
|
|
| Scientists engineered a type of CAR-T cells with a costimulatory signal that was activated independently from the tumor antigen to recapitulate physiological stimulation.
[Science Translational Medicine] |
|
|
|
| Kruppel-like factor 11 (KLF11) recruited SIN3A/HDAC to suppress the transcriptional output of YAP/TEAD, which, in turn, promoted KLF11 transcription, forming a negative feedback loop.
[Science Advances] |
|
|
|
| Using a forward genetic approach, researchers showed that a mutation in the SH3gl1 gene encoding the endocytic protein Endophilin A2 was associated with the development of arthritis in rodents.
[Nature Communications] |
|
|
|
| After a second-generation of CAR lentiviral construction, CD30 CAR T cells were produced and used to determine the cytotoxicity of this construct toward Karpas 299 cells.
[Cancer Gene Therapy] |
|
|
|
| When comparing the global gene expression of recently divided chronic lymphocytic leukemia cells with that of previously divided cells, researchers found higher levels of genes involved in regulating gene expression.
[Leukemia] |
|
|
|
| The authors identified CD93 as an important regulator of self-renewal and proliferation of murine and human leukemia stem cells, but not hematopoietic stem cells.
[Cell Reports] |
|
|
|
| Investigators utilized murine models of allogeneic hematopoietic cell transplantation to assess the role of stimulator of interferon genes (STING) in hematopoietic antigen-presenting cells.
[Cellular & Molecular Immunology] |
|
|
|
|
| Scientists present the current understanding, gaps in knowledge and future directions of research addressing CAR T cell-related adverse events.
[Nature Reviews Clinical Oncology] |
|
|
|
| The authors summarize current chimeric antigen receptor T cell (CAR-T) therapy targets in the treatment of hepatocellular carcinoma (HCC), discuss current obstacles and possible solutions in the process, and describe potential strategies to improve the efficacy of CAR-T cells for patients with HCC.
[Cancer Gene Therapy] |
|
|
|
|
| Kiromic BioPharma, Inc. announced the completion of the chPD1 licensing agreement with Longwood University.
[Kiromic BioPharma, Inc. (BusinessWire, Inc.)] |
|
|
|
|
| February 8 – 12, 2021
Virtual |
|
|
|
|
|
| | National Institutes of Health – Bethesda, Maryland, United States |
|
|
|
| | NIH National Cancer Institute – Bethesda, Maryland, United States |
|
|
|
| | University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
| | Stanford School of Medicine – Stanford, California, United States |
|
|
|
| | University of California San Francisco – San Francisco, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
